The interim analysis of the study has reported that after 3 years of PSA screening in men with germline BRCA1/2 mutations, those with a BRCA2 mutation had increased incidence of prostate cancer, younger age at diagnosis, and higher risk of developing clinically significant tumours [83]. The gene discussed is KLK3; the disease is neoplasm.